Epigral Limited has announced its un-audited financial results for the second quarter of fiscal year 2027. The company reported a significant 28% year-on-year revenue growth, reaching ₹752 Crore, driven by volume increases and improved realizations. Key financial highlights include a 26% growth in PAT to ₹64 Crore and strategic capital expenditure for new projects expected to commission by H2FY28.
Epigral Posts Strong Q2 FY27 Financials
Epigral Limited has released its investor presentation detailing the un-audited financial results for the second quarter (Q2) of the fiscal year 2027 (FY27). The company achieved a robust 28% year-on-year increase in revenue, amounting to ₹752 Crore, primarily attributed to volume growth and enhanced product realizations. This performance was achieved despite a challenging and volatile market environment.
Key Financial Highlights: Q2 FY27
- Sales Volume Growth: YoY sales volume grew by 6%.
- Revenue Growth: Revenue grew by 28% to ₹752 Crore.
- EBITDA: EBITDA grew by 3% to ₹136 Crore, with an EBITDA margin of 18%, impacted by high raw material costs.
- Profit After Tax (PAT): PAT grew by 26% to ₹64 Crore.
- Derivatives & Specialty Business: Contributed 57% of revenue.
Half Year Ended H1 FY27 Performance
For the first half of FY27 (H1FY27), Epigral reported a 21% increase in revenue to ₹1,461 Crore. EBITDA grew by 7% to ₹315 Crore, maintaining an EBITDA margin of 22%. PAT rose by 25% to ₹164 Crore, with a PAT margin of 11%.
Strategic Initiatives and Capex
Epigral spent ₹88 Crore on capex in H1FY27. The company’s board has approved capex for two key projects, the Epoxy Resin & Formulations plant (capacity 1,25,000 TPA) and a Multi-Purpose Plant (MPP), both expected to commission by H2FY28. These projects aim to strengthen the integrated complex and cater to growing demand in various industries.
CMD Message
Mr. Maulik Patel, Chairman and Managing Director, highlighted the Q2 FY27 revenue growth of 28%, driven by volume and realizations. He noted the impact of raw material prices on EBITDA margins but emphasized the resilient H1FY27 performance with 21% revenue growth and a 22% EBITDA margin. The company maintains a positive outlook for H2FY27, fueled by India’s demand growth and ongoing expansion plans, including the CPVC and ECH expansions nearing completion.
Source: BSE
